| HBS Case Collection
(Revised March 2006)
Molecular Insight Pharmaceuticals, Inc.
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing. Should it continue its current strategy or change its approach? Includes color exhibits.
Keywords: Intellectual Property;
Health Care and Treatment;